Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      And The Answer is No: Calcium and magnesium treatment do not reduce oxaliplatin-related neurotoxicity

      December 16, 2013
      By Lisa Schulmeister, RN, MN, APRN-BC, OCN, FAAN
      Article

      Neuropathy is a dose-limiting toxicity associated with oxaliplatin treatment. Clinical trials suggested that high doses of calcium and magnesium, given before and after oxaliplatin containing regimens, help prevent or reduce neuropathy. Consequently, calcium and magnesium administration was widely adopted in clinical practice.

      Neuropathy is a dose-limiting toxicity associated with oxaliplatin treatment. Clinical trials suggested that high doses of calcium and magnesium, given before and after oxaliplatin containing regimens, help prevent or reduce neuropathy. Consequently, calcium and magnesium administration was widely adopted in clinical practice. Two further clinical trials, however, were closed early when initial data suggested lower response rates in patients receiving calcium and magnesium (the response rate later was determined to be nearly identical to that of patients not receiving calcium and magnesium).

      The early discontinuation of the two clinical trials, the divergent results, and the widespread use of calcium and magnesium in clinical practice was the stimulus for a phase II N08CB/Alliance trial led by Charles Lopriniz, MD from the Mayo Clinic. Loprinzi and colleagues around the U.S. assessed whether calcium and magnesium treatment reduces oxaliplatin-related neurotoxicity in patients with colon cancer receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin). In the double-blind study, 353 patients receiving adjuvant FOLFOX were randomized into three groups. Group one received 1 Gram of calcium gluconate plus 1 Gram of magnesium sulfate immediately before and after chemotherapy. Group two received 1 Gram of magnesium sulfate immediately before chemotherapy and a placebo after chemotherapy. Group three received a placebo before and after chemotherapy. The primary endpoint was cumulative neurotoxicity measured by a validated neuropathy scale.

      The rates of grade 2 or higher neurotoxicity were 43% in the calcium/magnesium before and after group, 46% in the calcium/magnesium before and placebo after group, and 45% in the placebo before and after group. There were no significant differences between the two calcium/magnesium groups and the placebo group in the sensory neuropathy scale, on the motor neuropathy scale, or autonomic neuropathy scale. There were no significant differences in time to grade 2 or higher neuropathy on clinician assessment and there was no evidence of benefit of treatment in subgroups defined by age, sex, disease stage, and specific FOLFOX regimens. For acute neuropathy (within 5 days after each oxaliplatin dose), there was no beneficial effect of treatment in sensitivity to touching cold items, discomfort swallowing cold liquids, or muscle cramps. A small benefit was observed in reducing throat discomfort. There were no differences in toxicities among treatment groups (e.g. diarrhea, constipation, stomach cramping, bowel problems, and laboratory parameters). The researchers concluded that the data do not support using calcium and magnesium to protect against oxaliplatin-induced neuropathy.

      Reference

      Loprinzi CL, Qin R, Dakhil SR, et al. Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology, 2013. Published online before print 12/3/13, doi: 10.1200/JCO.2013.52.0536.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
      Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
      Photo of a man wearing a suit with a blue tie in front of a dark blue background
      4 experts in this video
      Related Content

      Graphic of malignant B cells

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Chris Ryan
      July 30th 2025
      Article

      Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Line illustration of lungs

      Opinion: Comprehensive Genomic Profiling Is Vital for Optimizing NSCLC Care

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      July 29th 2025
      Article

      Oncology nurses can ensure patients with non–small cell lung cancer receive the optimal treatment quickly by understanding comprehensive genomic profiling.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      graphic of a person with breast tumors

      JSKN003 Shows Activity in Heavily Pretreated HER2+ Breast Cancer

      Chris Ryan
      July 28th 2025
      Article

      Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.


      Graphic depicting red blood cells

      Generic Ibrutinib Tablet Given Tentative FDA Approval in CLL/SLL, WM

      Bridget Hoyt
      July 25th 2025
      Article

      A generic version of ibrutinib was granted tentative approval by the FDA for use in CLL and SLL with 17p deletion and Waldenström macroglobulinemia.

      Related Content

      Graphic of malignant B cells

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Chris Ryan
      July 30th 2025
      Article

      Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Line illustration of lungs

      Opinion: Comprehensive Genomic Profiling Is Vital for Optimizing NSCLC Care

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      July 29th 2025
      Article

      Oncology nurses can ensure patients with non–small cell lung cancer receive the optimal treatment quickly by understanding comprehensive genomic profiling.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      graphic of a person with breast tumors

      JSKN003 Shows Activity in Heavily Pretreated HER2+ Breast Cancer

      Chris Ryan
      July 28th 2025
      Article

      Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.


      Graphic depicting red blood cells

      Generic Ibrutinib Tablet Given Tentative FDA Approval in CLL/SLL, WM

      Bridget Hoyt
      July 25th 2025
      Article

      A generic version of ibrutinib was granted tentative approval by the FDA for use in CLL and SLL with 17p deletion and Waldenström macroglobulinemia.

      Latest Conference Coverage

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      Understanding How On-Target and Off-Target ADC Toxicities Work

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.